{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:55:07Z","timestamp":1793836507074,"version":"4.6.1"},"reference-count":54,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH-NCI","award":["R01CA260819"],"award-info":[{"award-number":["R01CA260819"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Head and neck squamous cell carcinoma (HNSCC) remains challenging to treat despite multimodal therapeutic approaches. Cisplatin treatment is effective and cost-efficient, although chemoresistance and disease recurrence limit its efficacy. Understanding the mechanisms of cisplatin resistance and the identification of compounds to target resistant tumor cells are critical for improving patient outcomes. We have demonstrated that cisplatin-induced senescent HN30 HNSCC cells can be eliminated by ABT-263 (navitoclax), a BCL-2\/BCL-XL inhibitor that has senolytic properties. Here, we report the development of a cisplatin-resistant cell line (HN30R) for the testing of ABT-263 and the PROTAC BET degraders ARV-825 and ARV-771. ABT-263 was ineffective in sensitizing HN30R cells to cisplatin, largely due to a lack of senescence induction. However, the BET degraders in combination with cisplatin promoted apoptotic cell death in both HN30 and HN30R cells. The effectiveness of ARV-825 did not appear to depend on the cells entering into senescence, indicating that it was not acting as a conventional senolytic. ARV-825 treatment downregulated BRD4 and its downstream targets, c-Myc and Survivin, as well as decreased the expression of RAD51, a DNA repair marker. These results suggest that the BET degraders ARV-825 and ARV-771 may be effective in improving the response of chemoresistant head and neck cancer to cisplatin treatment.<\/jats:p>","DOI":"10.3390\/ijms26136185","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T03:33:25Z","timestamp":1750995205000},"page":"6185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells"],"prefix":"10.3390","volume":"26","author":[{"given":"Natalie","family":"Luffman","sequence":"first","affiliation":[{"name":"Department of Human and Molecular Genetics, School of Medicine, Philips Institute for Oral Health Research, School of Dentistry, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Ahmadinejad","sequence":"additional","affiliation":[{"name":"Department of Human and Molecular Genetics, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-6906","authenticated-orcid":false,"given":"Ryan M.","family":"Finnegan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Raymond","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0437-4934","authenticated-orcid":false,"given":"David A.","family":"Gewirtz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-1289","authenticated-orcid":false,"given":"Hisashi","family":"Harada","sequence":"additional","affiliation":[{"name":"Philips Institute for Oral Health Research, School of Dentistry, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/BTT.S43628","article-title":"Cetuximab: Its Unique Place in Head and Neck Cancer Treatment","volume":"7","author":"Vermorken","year":"2013","journal-title":"Biol. Targets Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000477127","article-title":"Epidemiology and Molecular Biology of Head and Neck Cancer","volume":"40","author":"Jou","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular Mechanisms of Cisplatin Resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and Cancer\u2014Role and Therapeutic Opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jncc.2023.09.001","article-title":"Therapy-Induced Senescent Tumor Cells in Cancer Relapse","volume":"3","author":"Song","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/0008-5472.CAN-24-2219","article-title":"A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment","volume":"85","author":"Saleh","year":"2025","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/molpharm.121.000354","article-title":"Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin","volume":"101","author":"Ahmadinejad","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Carpenter, V.J., Saleh, T., and Gewirtz, D.A. (2021). Senolytics for Cancer Therapy: Is All That Glitters Really Gold?. Cancers, 13.","DOI":"10.3390\/cancers13040723"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/1535-7163.MCT-22-0643","article-title":"Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer","volume":"22","author":"Kieran","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting Senescence for the Treatment of Cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111888","DOI":"10.1016\/j.mad.2023.111888","article-title":"Current Senolytics: Mode of Action, Efficacy and Limitations, and Their Future","volume":"217","author":"Rad","year":"2024","journal-title":"Mech. Ageing Dev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","article-title":"Clearance of Therapy-induced Senescent Tumor Cells by the Senolytic ABT-263 via Interference with BCL-X L \u2013BAX Interaction","volume":"14","author":"Saleh","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Softah, A., Alotaibi, M.R., Alhoshani, A.R., Saleh, T., Alhazzani, K., Almutairi, M.M., AlRowis, R., Alshehri, S., Albekairy, N.A., and Harada, H. (2023). The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113066"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sato, K., Iwasaki, S., and Yoshino, H. (2021). Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413233"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","article-title":"BH3 Mimetics Selectively Eliminate Chemotherapy-Induced Senescent Cells and Improve Response in TP53 Wild-Type Breast Cancer","volume":"27","author":"Shahbandi","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sharma, A.K., Roberts, R.L., Benson, R.D., Pierce, J.L., Yu, K., Hamrick, M.W., and McGee-Lawrence, M.E. (2020). The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00354"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a Novel Senolytic Agent, Navitoclax, Targeting the Bcl-2 Family of Anti-apoptotic Factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting Selective BCL-2 Family Inhibitors to Dissect Cell Survival Dependencies and Define Improved Strategies for Cancer Therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/0008-5472.CAN-18-3223","article-title":"BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5","volume":"79","author":"Tan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving Clinical Success with BET Inhibitors as Anti-Cancer Agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-0459","article-title":"BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC","volume":"78","author":"Leonard","year":"2018","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.31581","article-title":"Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma","volume":"9","author":"Wu","year":"2019","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 Ligases against Each Other Using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: Going beyond Transcriptional Regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1111\/febs.16580","article-title":"BRD4 and MYC: Power Couple in Transcription and Disease","volume":"290","author":"Kotekar","year":"2023","journal-title":"FEBS J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/s41467-020-15719-6","article-title":"A BET Family Protein Degrader Provokes Senolysis by Targeting NHEJ and Autophagy in Senescent Cells","volume":"11","author":"Wakita","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Li, Z., Lim, S.L., Tao, Y., Li, X., Xie, Y., Yang, C., Zhang, Z., Jiang, Y., Zhang, X., and Cao, X. (2020). PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.574525"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Liao, X., Qian, X., Zhang, Z., Tao, Y., Li, Z., Zhang, Q., Liang, H., Li, X., Xie, Y., and Zhuo, R. (2021). ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.753119"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Elshazly, A.M., Sinanian, M.M., Neely, V., Chakraborty, E., Alshehri, M.A., McGrath, M.K., Harada, H., Schoenlein, P.V., and Gewirtz, D.A. (2023). BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15164066"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Finnegan, R.M., Elshazly, A.M., Patel, N.H., Tyutyunyk-Massey, L., Tran, T.H., Kumarasamy, V., Knudsen, E.S., and Gewirtz, D.A. (2022). The BET Inhibitor\/Degrader ARV-825 Prolongs the Growth Arrest Response to Fulvestrant + Palbociclib and Suppresses Proliferative Recovery in ER-Positive Breast Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.966441"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Deng, Y., Yu, C., Chen, L., Zhang, X., Lei, Q., Liu, Q., Cai, G., and Liu, F. (2022). ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.858901"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-Induced BET Protein Degradation as a Therapy for Castration-Resistant Prostate Cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients with Unresectable Squamous Cell Head and Neck Cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and Neck Squamous Cell Carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V108.11.1107.1107","article-title":"The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice","volume":"108","author":"Shoemaker","year":"2006","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100712","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the Inhibitors: Targeting Anti-Apoptotic Proteins in Cancer and Therapy Resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer","volume":"Volume 137","author":"Maji","year":"2018","journal-title":"Advances in Cancer Research"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sarnik, J., Pop\u0142awski, T., and Tokarz, P. (2021). BET Proteins as Attractive Targets for Cancer Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011102"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/s41467-022-30787-6","article-title":"BRD4 Promotes Resection and Homology-Directed Repair of DNA Double-Strand Breaks","volume":"13","author":"Barrows","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1101\/gad.300079.117","article-title":"Glioblastoma Cellular Cross-Talk Converges on NF-\u03baB to Attenuate EGFR Inhibitor Sensitivity","volume":"31","author":"Zanca","year":"2017","journal-title":"Genes Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13046-019-1387-5","article-title":"Activity of BET-Proteolysis Targeting Chimeric (PROTAC) Compounds in Triple Negative Breast Cancer","volume":"38","author":"Burgos","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1038\/s41467-020-17503-y","article-title":"BRD4 Prevents the Accumulation of R-Loops and Protects against Transcription\u2013Replication Collision Events and DNA Damage","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to Detect Senescence-Associated Beta-Galactosidase (SA-\u0392gal) Activity, a Biomarker of Senescent Cells in Culture and in Vivo","volume":"4","author":"Erusalimsky","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ebiom.2019.01.056","article-title":"Senolytics and Senostatics as Adjuvant Tumour Therapy","volume":"41","author":"Short","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0026-0495(98)90120-2","article-title":"Use of a Soluble Tetrazolium Compound to Assay Metabolic Activation of Intact Beta Cells","volume":"47","author":"Segu","year":"1998","journal-title":"Metabolism"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","article-title":"A Biomarker That Identifies Senescent Human Cells in Culture and in Aging Skin in Vivo","volume":"92","author":"Dimri","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","first-page":"e64176","article-title":"Far-Red Fluorescent Senescence-Associated \u03b2-Galactosidase Probe for Identification and Enrichment of Senescent Tumor Cells by Flow Cytometry","volume":"187","author":"Flor","year":"2022","journal-title":"J. Vis. Exp."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:59:42Z","timestamp":1760032782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":54,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136185"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136185","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}